Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

According to Citi, the delay in the launch of Sun Pharma's alopecia areata drug, Leqselvi, could impact its near-term ...

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Sun Pharmaceuticals Ltd. announced on Saturday that the US District Court of New Jersey has granted a preliminary injunction ...

After a US Court blocked the launch of Leqselvi, a drug used to treat severe alopecia areata, shares of Sun Pharma plunged ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

Leqselvi, projected to generate around $200 million in sales over the next three to four years for Sun Pharma, was slated for ...

Shares of Sun Pharmaceuticals dropped 3.5% after a court in New Jersey issued an injunction delaying the launch of its drug ...

Given the investments of around $576 million and the peak revenues potential upwards of $200 million, four years down the ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...